Published in Clin Cancer Res on December 15, 2008
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther (2009) 2.21
Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol (2012) 2.09
Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest (2010) 1.97
Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ (2013) 1.42
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res (2010) 1.35
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol (2010) 1.26
The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment. Genes Cancer (2011) 1.23
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov (2013) 1.21
GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis (2010) 1.17
Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br J Pharmacol (2014) 1.13
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer (2011) 1.10
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opin Ther Pat (2011) 1.04
Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol (2011) 1.04
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer (2012) 1.03
A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res (2010) 1.02
Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer (2010) 1.00
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood (2013) 0.99
GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther (2013) 0.97
Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs (2013) 0.92
Harnessing the cell death pathway for targeted cancer treatment. Am J Cancer Res (2010) 0.91
An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid (2013) 0.91
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biol Ther (2013) 0.89
Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? Cell Death Dis (2014) 0.89
Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors. Commun Integr Biol (2012) 0.88
Anti-apoptotic genes in the survival of monocytic cells during infection. Curr Genomics (2009) 0.88
Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? Immunol Rev (2015) 0.88
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Neoplasia (2011) 0.87
Manipulating the apoptotic pathway: potential therapeutics for cancer patients. Br J Clin Pharmacol (2013) 0.86
Update on rational targeted therapy in AML. Blood Rev (2016) 0.85
Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma (2014) 0.85
A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. PLoS One (2014) 0.85
Why anti-Bcl-2 clinical trials fail: a solution. Cancer Metastasis Rev (2014) 0.84
Host-based Prophylaxis Successfully Targets Liver Stage Malaria Parasites. Mol Ther (2015) 0.82
BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis. Clin Cancer Res (2015) 0.82
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. J Thorac Oncol (2014) 0.81
Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol (2014) 0.81
Small-molecule inhibitors reveal a new function for Bcl-2 as a proangiogenic signaling molecule. Curr Top Microbiol Immunol (2011) 0.81
Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta Neuropathol Commun (2014) 0.81
Apoptosis in leukemias: regulation and therapeutic targeting. Cancer Treat Res (2010) 0.81
MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematol (2013) 0.80
Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia. PLoS One (2013) 0.80
Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Oncotarget (2016) 0.80
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Clin Cancer Res (2016) 0.80
The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma. Int J Mol Sci (2015) 0.78
Reactive oxygen species in eradicating acute myeloid leukemic stem cells. Stem Cell Investig (2014) 0.77
Tailored fragments of roseophilin selectively antagonize Mcl-1 in vitro. Tetrahedron Lett (2015) 0.77
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. Leuk Lymphoma (2014) 0.76
Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells. PLoS One (2012) 0.76
Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells. Proc Natl Acad Sci U S A (2016) 0.75
Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation. Front Pediatr (2016) 0.75
Targeting apoptosis in acute myeloid leukaemia. Br J Cancer (2017) 0.75
BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells. Oncotarget (2016) 0.75
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer. Int J Mol Sci (2017) 0.75
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med (2012) 9.69
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 7.83
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res (2006) 7.18
Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med (2012) 6.99
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2006) 6.89
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol (2014) 6.61
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest (2005) 5.91
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med (2010) 5.68
Positron-emission tomography and assessment of cancer therapy. N Engl J Med (2006) 5.43
Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst (2004) 5.39
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 5.17
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res (2002) 4.99
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92
Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg (2009) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood (2010) 4.51
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis (2005) 4.31
Measuring patients' experiences with individual primary care physicians. Results of a statewide demonstration project. J Gen Intern Med (2006) 4.17
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis (2004) 4.15
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol (2005) 4.06
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res (2005) 4.00
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2008) 3.97
Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood (2002) 3.97
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood (2013) 3.91
Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One (2009) 3.89
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw (2008) 3.82
MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A (2006) 3.80
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 3.76
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer (2008) 3.75
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell (2007) 3.47
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood (2002) 3.46
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood (2007) 3.29
MicroRNA 29b functions in acute myeloid leukemia. Blood (2009) 3.19
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18